S&P 500   3,971.96 (+0.89%)
DOW   32,233.70 (+0.64%)
QQQ   312.53 (+2.09%)
AAPL   160.46 (+1.67%)
MSFT   280.18 (+2.90%)
META   206.57 (+3.38%)
GOOGL   105.94 (+2.49%)
AMZN   100.26 (+1.58%)
TSLA   195.62 (+2.34%)
NVDA   273.60 (+3.37%)
NIO   9.31 (+2.42%)
BABA   86.55 (+3.47%)
AMD   101.60 (+4.12%)
T   18.52 (+0.71%)
F   11.62 (+1.22%)
MU   61.29 (+5.36%)
CGC   1.90 (+1.07%)
GE   92.04 (+2.73%)
DIS   96.72 (+1.92%)
AMC   4.52 (+4.15%)
PFE   40.45 (+1.10%)
PYPL   73.35 (-1.33%)
NFLX   320.45 (+9.03%)
S&P 500   3,971.96 (+0.89%)
DOW   32,233.70 (+0.64%)
QQQ   312.53 (+2.09%)
AAPL   160.46 (+1.67%)
MSFT   280.18 (+2.90%)
META   206.57 (+3.38%)
GOOGL   105.94 (+2.49%)
AMZN   100.26 (+1.58%)
TSLA   195.62 (+2.34%)
NVDA   273.60 (+3.37%)
NIO   9.31 (+2.42%)
BABA   86.55 (+3.47%)
AMD   101.60 (+4.12%)
T   18.52 (+0.71%)
F   11.62 (+1.22%)
MU   61.29 (+5.36%)
CGC   1.90 (+1.07%)
GE   92.04 (+2.73%)
DIS   96.72 (+1.92%)
AMC   4.52 (+4.15%)
PFE   40.45 (+1.10%)
PYPL   73.35 (-1.33%)
NFLX   320.45 (+9.03%)
S&P 500   3,971.96 (+0.89%)
DOW   32,233.70 (+0.64%)
QQQ   312.53 (+2.09%)
AAPL   160.46 (+1.67%)
MSFT   280.18 (+2.90%)
META   206.57 (+3.38%)
GOOGL   105.94 (+2.49%)
AMZN   100.26 (+1.58%)
TSLA   195.62 (+2.34%)
NVDA   273.60 (+3.37%)
NIO   9.31 (+2.42%)
BABA   86.55 (+3.47%)
AMD   101.60 (+4.12%)
T   18.52 (+0.71%)
F   11.62 (+1.22%)
MU   61.29 (+5.36%)
CGC   1.90 (+1.07%)
GE   92.04 (+2.73%)
DIS   96.72 (+1.92%)
AMC   4.52 (+4.15%)
PFE   40.45 (+1.10%)
PYPL   73.35 (-1.33%)
NFLX   320.45 (+9.03%)
S&P 500   3,971.96 (+0.89%)
DOW   32,233.70 (+0.64%)
QQQ   312.53 (+2.09%)
AAPL   160.46 (+1.67%)
MSFT   280.18 (+2.90%)
META   206.57 (+3.38%)
GOOGL   105.94 (+2.49%)
AMZN   100.26 (+1.58%)
TSLA   195.62 (+2.34%)
NVDA   273.60 (+3.37%)
NIO   9.31 (+2.42%)
BABA   86.55 (+3.47%)
AMD   101.60 (+4.12%)
T   18.52 (+0.71%)
F   11.62 (+1.22%)
MU   61.29 (+5.36%)
CGC   1.90 (+1.07%)
GE   92.04 (+2.73%)
DIS   96.72 (+1.92%)
AMC   4.52 (+4.15%)
PFE   40.45 (+1.10%)
PYPL   73.35 (-1.33%)
NFLX   320.45 (+9.03%)
NYSE:QGEN

Qiagen - QGEN Stock Forecast, Price & News

$46.22
+0.28 (+0.61%)
(As of 03/23/2023 01:03 PM ET)
Add
Compare
Today's Range
$45.89
$46.48
50-Day Range
$45.29
$50.65
52-Week Range
$40.38
$51.18
Volume
147,450 shs
Average Volume
666,995 shs
Market Capitalization
$10.53 billion
P/E Ratio
25.12
Dividend Yield
N/A
Price Target
$55.53

Qiagen MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
20.4% Upside
$55.53 Price Target
Short Interest
Bearish
2.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.32mentions of Qiagen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.53%
From $2.11 to $2.29 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

558th out of 986 stocks

Biological Products, Except Diagnostic Industry

97th out of 165 stocks


QGEN stock logo

About Qiagen (NYSE:QGEN) Stock

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Qiagen Full Year 2022 Earnings: EPS Misses Expectations
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen
QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
See More Headlines
Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Company Calendar

Last Earnings
2/07/2023
Today
3/23/2023
Next Earnings (Estimated)
4/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Employees
6,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.53
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$52.00
Forecasted Upside/Downside
+20.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$423.21 million
Pretax Margin
23.94%

Debt

Sales & Book Value

Annual Sales
$2.14 billion
Cash Flow
$3.49 per share
Book Value
$15.27 per share

Miscellaneous

Free Float
206,637,000
Market Cap
$10.50 billion
Optionable
Optionable
Beta
0.40

Key Executives

  • Thierry Bernard
    Chief Executive Officer & Managing Director
  • Antonio Santos
    Senior Vice President & Head-Global Operations
  • Roland Sackers
    Chief Financial Officer & Managing Director
  • Philipp von Hugo
    VP, Head-Global Legal Affairs & Compliance
  • Lezette Young
    Manager-Compliance & Legal













QGEN Stock - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" QGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares.
View QGEN analyst ratings
or view top-rated stocks.

What is Qiagen's stock price forecast for 2023?

5 brokers have issued 12-month target prices for Qiagen's stock. Their QGEN share price forecasts range from $52.00 to $60.00. On average, they anticipate the company's share price to reach $55.53 in the next year. This suggests a possible upside of 20.9% from the stock's current price.
View analysts price targets for QGEN
or view top-rated stocks among Wall Street analysts.

How have QGEN shares performed in 2023?

Qiagen's stock was trading at $49.87 at the start of the year. Since then, QGEN stock has decreased by 7.9% and is now trading at $45.94.
View the best growth stocks for 2023 here
.

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our QGEN earnings forecast
.

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) posted its quarterly earnings data on Tuesday, February, 7th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.47 by $0.06. The business had revenue of $531 million for the quarter, compared to analyst estimates of $486.93 million. Qiagen had a net margin of 19.76% and a trailing twelve-month return on equity of 16.45%. Qiagen's revenue was down 8.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.74 EPS.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen issued an update on its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided earnings per share guidance of $2.10- for the period, compared to the consensus EPS estimate of $2.12. The company issued revenue guidance of $2.05B-, compared to the consensus revenue estimate of $2.07 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are Qiagen's major shareholders?

Qiagen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Amundi (3.27%), Norges Bank (2.53%), Pendal Group Ltd (1.89%), Arrowstreet Capital Limited Partnership (1.63%), Morgan Stanley (1.28%) and Marshall Wace LLP (0.97%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $45.94.

How much money does Qiagen make?

Qiagen (NYSE:QGEN) has a market capitalization of $10.46 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.84 on an earnings per share basis.

How many employees does Qiagen have?

The company employs 6,000 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.

This page (NYSE:QGEN) was last updated on 3/23/2023 by MarketBeat.com Staff